Summary:
In this podcast, featuring a panel discussion from the 2025 Chief Medical Officer Summit 360°, CMOs with recent M&A and partnership experience share those experiences as well as how CMOs of other small to midsize emerging biotech companies can support the conversations and operations that take place throughout the process of business development. Specifically:
- Different kinds of BD deals to be aware of
- How the CMO fits into various phases of transactions
- Appreciating how different c-suite colleagues and direct reports experience these transactions
- The different pharma teams CMOs will interact with
- What happens after the acquisition
To learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.
Moderators
Howard Rutman, MD, MBA
CMO
Xalud Therapeutics
Panelists
Simon Cooper, MBBS
CMO
LifeMine Therapeutics
Randall Kaye, MD
Chief Medical Advisor
NervGen
Yaping Shou, MD, PhD
Founder & CEO
Wells Therapeutics
Qing Yu Christina Weng, MD
CMO
Pelage Pharmaceuticals
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work.